Research in the journal Plos One shows that misshapen red blood cells could be used as a tool to kill cancer cells, according to experiments carried out on mice. The researchers involved say that sickle-shaped cells can stick together in blood vessels surrounding tumours, blocking blood flow to the cancer. The blood cells are also able to deposit toxic residues on the tumour, leading to the death of the cancer cells. The research in question focused on the oxygen-poor areas of tumours, which have proven difficult to treat in humans.
The US researchers from Duke University and Jenomic, a private research company, gave mice with cancer a fluorescent sickle-cell solution and observed what happened within their systems. Prof. Mark Dewhirst from Duke University, who was co-author of the study, said that in less than five minutes the misshapen cells had begun to stick like 'Velcro' to blood vessels near oxygen-starved areas of the tumour. At 30 minutes the cells began to form clots and block the small blood vessels which fed the tumour, once this had happened they then deposited the toxic residue which killed the tumour cells. An additional bonus is that the sickle-shaped cells exclusively targeted the oxygen-low areas of the tumour, which can become increasingly aggressive forms of cancer in humans.
The sickle cells used in the study are the exact same type that can be found in people with sickle-cell anaemia, which unlike normal erythrocytes are crescent-moon shaped and can clump together in blood vessels rather than flowing through smoothly. Dr David Terman, another co-author of the study and head of molecular genetics at Jenomic said: "The very qualities that make sickle cells a danger to people with the inherited genetic disorder can be turned against tumours to fight cancer."
This is an intriguing new tactic for destroying tumours that are resistant to standard treatments, but as with all therapies tested on mice the next challenge is to determine whether they are safe and effective in humans. The researchers say that the approach could be directed at breast cancers, prostate cancers and many other tumours that develop resistance to current therapies, once more animal studies and human trials have been conducted.
Jack

Love your blog and purpose; keep posting amazing entries!! Xx. :)
ReplyDelete